Top segments and regional performance

Last year, the company generated ‪8.00 K‬ USD, the most of which — ‪8.00 K‬ USD — came from its top-performing segment, Oncolytic Immunotherapies, compared to ‪8.00 K‬ USD the previous year. The greatest contribution came from United States, which accounted for ‪8.00 K‬ USD last year, with ‪8.00 K‬ USD the year before.